Debio 4326
Phase 3
Debio 4326 is one of 13 therapeutic programs targeting Central precocious puberty. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
16 competitors in Central Precocious Puberty
#DrugCompanyPhaseTrials
1Megace
Bristol-Myers SquibbApproved
Lupron
AbbVieApproved
Leuprorelin
TakedaApproved
Lupron
EEastern Cooperative Oncology Group
Phase 3
Trelstar
OOncoVerity, Inc.
Phase 3
Triptorelin Pamoate
IpsenPhase 3
Debio 025
DDebiopharm International SA
Phase 3
Supprelin La
UUniversity of Hertfordshire
Phase 3
Eligard
HHanAll BioPharma Co., Ltd.
Approved
Leuprolide Mesylate
FForesee Pharmaceuticals Co., Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Debio 4326. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]
- Company
- DDebiopharm International SA